secwatch / observer
8-K filed October 29, 2021, 7:59 PM ET ticker CRMD CIK 0001410098
leadership confidence high sentiment neutral materiality 0.55

CorMedix CFO Matt David appointed interim CEO; salary to $425k, bonus 60%

CorMedix Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Matt David

interim Chief Executive Officer
CRMD · CorMedix Inc.
Effective
2021-10-26
Filed
October 29, 2021, 7:59 PM ET
On October 26, 2021, CorMedix Inc. (“Company”) and Matt David, M.D., the Company’s current Chief Financial Officer, entered into a letter agreement (the “Letter Agreement”) modifying certain terms of his employment agreement with the Company, dated May 11, 2020 (“Employment Agreement”), and providing other compensation, as a result of Dr. David serving as interim Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matt David was appointed as interim Chief Executive Officer at CorMedix Inc..

Action
appointed
Role
interim Chief Executive Officer
Exact text from the filing
On October 26, 2021, CorMedix Inc. (“Company”) and Matt David, M.D., the Company’s current Chief Financial Officer, entered into a letter agreement (the “Letter Agreement”) modifying certain terms of his employment agreement with the Company, dated May 11, 2020 (“Employment Agreement”), and providing other compensation, as a result of Dr. David serving as interim Chief Executive Officer of the Company.
View on SEC.gov

CorMedix Inc. filing history →

Source: SEC EDGAR
accession 0001213900-21-055420
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.